Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Study to Evaluate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

Next Previous
Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Study to Evaluate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Verekitug (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms VALIANT
  • Sponsors Upstream Biosciences

Most Recent Events

  • 12 Jun 2025 Status changed from recruiting to active, no longer recruiting.
  • 06 May 2025 According to Upstream Bio media release, company has designed this trial using endpoints that, pending interactions with regulatory authorities, could produce data to support submissions for product approval.
  • 07 Nov 2024 According to Upstream Bio media release, company expect to report top-line data from this trial in second half of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top